Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tucatinib

- PMLiVE

Roche blasts UK’s ‘broken’ HTA system as Kadcyla rejected

But NICE says it is 'very disappointed' with the company's pricing policy

- PMLiVE

Nexavar fails late-stage breast cancer trial

Bayer’s oncology drug unable to improve progression free survival in new indication

Roche - Basel

Roche makes $1.7bn oncology acquisition

Takes over Seragon and its pipeline of investigational breast cancer treatments

- PMLiVE

NICE rejects Roche’s Kadcyla as “unaffordable”

Cancer drug unable to justify £90,000 price tag

- PMLiVE

Pfizer’s breast cancer drug palbociclib extends survival

Positive trial results for oncology treatment

- PMLiVE

Biocon plans February launch for first biosimilar Herceptin

Set to market own version of breast cancer drug in India

- PMLiVE

The oncology market in Canada

Ten per cent is not enough - simple estimates of the Canadian oncology market overlook a complex picture

Roche - Basel

EU backs Roche’s Kadcyla in breast cancer

Green light for Herceptin follow-up

- PMLiVE

Buildings light up pink for breast cancer

Part of 'Wear it pink' day for  Breast Cancer Campaign

- PMLiVE

FDA gives green light to Roche for early Perjeta in breast cancer

Oncology drug can now be used before surgery in the US

- PMLiVE

UK breast cancer campaign tackles confidence failings

Breast Cancer Care aims to address negative impact on how women feel about their bodies

- PMLiVE

Mixed news for Lilly on cancer hope ramucirumab

Fails in phase III for breast cancer but better results for stomach cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links